Connection

Fernando Bozza to Antiviral Agents

Back to Details
This is a "connection" page, showing publications Fernando Bozza has written about Antiviral Agents.
Fernando Bozza
Connection Strength
0.081
Antiviral Agents
  1. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production. Antimicrob Agents Chemother. 2020 09 21; 64(10).
    View in: PubMed
    Score: 0.021
  2. Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo. PLoS Negl Trop Dis. 2019 01; 13(1):e0007072.
    View in: PubMed
    Score: 0.019
  3. Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae. Sci Rep. 2017 08 25; 7(1):9409.
    View in: PubMed
    Score: 0.017
  4. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci Rep. 2017 01 18; 7:40920.
    View in: PubMed
    Score: 0.016
  5. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. J Antimicrob Chemother. 2021 06 18; 76(7):1874-1885.
    View in: PubMed
    Score: 0.005
  6. H1N1pdm influenza infection in hospitalized cancer patients: clinical evolution and viral analysis. PLoS One. 2010 Nov 30; 5(11):e14158.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.